Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 5Completed 3Not yet recruiting 2Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 24Carcinoma, Renal Cell 15Carcinoma, Non-Small-Cell Lung 15Neoplasm Metastasis 12Urinary Bladder Neoplasms 6Sarcoma 6Prostatic Neoplasms 6Lung Neoplasms 6Pancreatic Neoplasms 5Neoplasms 5Kidney Neoplasms 5Ovarian Neoplasms 4Glioblastoma 4Carcinoma, Transitional Cell 4Uveal Melanoma 3Small Cell Lung Carcinoma 3Myelodysplastic Syndromes 3Mesothelioma 3Histiocytoma, Malignant Fibrous 3Colorectal Neoplasms 3Chordoma 3Carcinoma, Neuroendocrine 3Carcinoma, Merkel Cell 3Breast Neoplasms 3Brain Neoplasms 3Urogenital Neoplasms 2Urethral Neoplasms 2Ureteral Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2

Interventions

cabozantinib 2pembrolizumab 1lenvatinib 1fludarabine 1Selenomethionine 1Nivolumab 1Ipilimumab 1Everolimus 1Cyclophosphamide 1CTLA-4 Antigen 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Clear-cell metastatic renal cell carcinoma × Ipilimumab × Clear all
NCT04388852 2026-05-20

DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
65 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡